Candriam SCA’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Candriam SCA’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-16,000	Closed	-$887K	–	823
2019 Q2	$887K	Sell	16,000 -8,000	-33%	-$417K	0.01%	671
2019 Q1	$1.21M	Hold	24,000	–	–	0.02%	591
2018 Q4	$967K	Hold	24,000	–	–	0.01%	589
2018 Q3	$1.66M	Hold	24,000	–	–	0.02%	541
2018 Q2	$1.82M	Hold	24,000	–	–	0.03%	509
2018 Q1	$1.26M	Hold	24,000	–	–	0.02%	552
2017 Q4	$1.28M	Sell	24,000 -35,000	-59%	-$1.95M	0.02%	535
2017 Q3	$3.52M	Buy	59,000 +11,000	+23%	+$665K	0.06%	343
2017 Q2	$3.79M	Hold	48,000	–	–	0.07%	328
2017 Q1	$3.98M	Sell	48,000 -14,000	-23%	-$1.04M	0.08%	299
2016 Q4	$4.92M	Sell	62,000 -5,000	-7%	-$363K	0.11%	215
2016 Q3	$4.69M	Buy	67,000 +12,000	+22%	+$665K	0.11%	201
2016 Q2	$2.13M	Sell	55,000 -2,500	-4%	-$104K	0.06%	299
2016 Q1	$2.32M	Buy	+57,500	New	+$3.65M	0.06%	299

Other funds holding EGRX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

HEC

Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Candriam SCA's EGRX Position: Q3 2019 in Review

Candriam SCA sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2019, closing a stake of 16,000 shares — an estimated $887K sold.

Candriam SCA first reported a position in EGRX in Q1 2016 and held it in 14 quarters. The position peaked at $4.92M in Q4 2016. 183 funds tracked by Wall St. Rank hold EGRX as of Q3 2019.

Candriam SCA reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
Candriam SCA sold 16,000 Eagle Pharmaceuticals, Inc. shares in Q3 2019, an estimated $887K.
Candriam SCA first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2016 and held it in 14 quarters.
Candriam SCA's Eagle Pharmaceuticals, Inc. position peaked at $4.92M in Q4 2016.
183 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2019.

Based on Candriam SCA's 13F filing for Q3 2019, filed 21 Oct 2019.